Siobhan Laws

Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Joyce O’Shaughnessy, Joanne L. Blum, Vladimir Moiseyenko et al. · Annals of Oncology · 2001 · 305 citations · Full text

Medicine, Oncology, Pharmacology +13

Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial

Jayant S. Vaidya, Max Bulsara, Michael Baum et al. · BMJ · 2020 · 289 citations · Full text

Medicine, Oncology, Surgery +17

Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study

Shelley Potter, Elizabeth J. Conroy, Ramsey I Cutress et al. · The Lancet Oncology · 2019 · 202 citations · Full text

Medicine, Plastic Surgery, Surgery +16

Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines

Denis Talbot, Vladimir Moiseyenko, Simon Van Belle et al. · British Journal of Cancer · 2002 · 181 citations · Full text

Medicine, Oncology, Pharmacology +15

Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival

Jayant S. Vaidya, Max Bulsara, Christobel Saunders et al. · JAMA Oncology · 2020 · 106 citations · Full text

Medicine, Oncology, Surgery +17